Valuation: TScan Therapeutics, Inc.

Market Cap 9.89M 9.01M 8.3M 7.55M 14.16M 916M 14.88M 101M 40.15M 500M 37.1M 36.32M 1.57B P/E 2026 *
-0.17x
P/E 2027 * -0.26x
Enterprise Value 9.89M 9.01M 8.3M 7.55M 14.16M 916M 14.88M 101M 40.15M 500M 37.1M 36.32M 1.57B EV / Sales 2026 *
3.78x
EV / Sales 2027 * 7.91x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: TScan Therapeutics, Inc.

1 day+2.24%
1 week-9.15%
Current month-16.39%
1 month-34.87%
3 months-81.28%
6 months-85.70%
Current year-85.41%
1 week 0.14
Extreme 0.14
0.17
1 month 0.14
Extreme 0.14
0.23
Current year 0.14
Extreme 0.14
1.47
1 year 0.14
Extreme 0.14
1.47
3 years 0.14
Extreme 0.14
9.69
5 years 0.14
Extreme 0.14
9.69
10 years 0.14
Extreme 0.14
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Chief Tech/Sci/R&D Officer - 06/02/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Free

Chief Executive Officer

1,000,000 1.5747%
1/10/26 Free

General Counsel

300,000 0.4724%
20/5/26 Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+2.24%-9.15%-84.85%-96.51% 9.89M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.01%-2.01%+21.28%+152.83% 40B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.16%

Financials

2026 *2027 *
Net sales 2.62M 2.39M 2.2M 2M 3.75M 243M 3.94M 26.75M 10.63M 132M 9.83M 9.62M 416M 1.25M 1.14M 1.05M 954K 1.79M 116M 1.88M 12.77M 5.07M 63.22M 4.69M 4.59M 198M
Net income -113M -103M -95.02M -86.43M -162M -10.48B -170M -1.16B -460M -5.73B -425M -416M -17.97B -73.48M -66.92M -61.67M -56.09M -105M -6.8B -111M -751M -298M -3.72B -276M -270M -11.66B
Net Debt - -
Projected Income Statement - Annual - TScan Therapeutics, Inc.
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45.
Employees
43
Date Price Change Volume
20/11/26 USD 0.1459 +2.24% 391,759
19/11/26 USD 0.1427 -3.84% 507,198
18/11/26 USD 0.1484 -1.72% 656,745
17/11/26 USD 0.1510 +4.07% 310,648
16/11/26 USD 0.1451 -9.65% 404,948
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - TScan Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.1459USD
Average target price
1.000USD
Spread / Average Target
+585.40%
  1. Stock Market
  2. Stocks
  3. TCRX Stock